The global Osteoporosis Biosimilars market size is predicted to grow from US$ 1890 million in 2025 to US$ 2341 million in 2031; it is expected to grow at a CAGR of 3.6% from 2025 to 2031.
Osteoporosis biosimilars are a class of follow-up biologic products that are equivalent to approved osteoporosis biologic drugs in quality, safety and efficacy. They go through a rigorous regulatory process and demonstrate no significant differences in key properties from the original drug, providing patients with additional treatment options and potentially increasing treatment accessibility due to their lower cost.
United States market for Osteoporosis Biosimilars is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Osteoporosis Biosimilars is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Osteoporosis Biosimilars is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Osteoporosis Biosimilars players cover Biosidus SA, Cadila Pharmaceuticals, Gedeon Richter Australia Pty Ltd, Mochida Pharmaceutical Co., Ltd, STADA Arzneimittel AG, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淥steoporosis Biosimilars Industry Forecast鈥� looks at past sales and reviews total world Osteoporosis Biosimilars sales in 2024, providing a comprehensive analysis by region and market sector of projected Osteoporosis Biosimilars sales for 2025 through 2031. With Osteoporosis Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Osteoporosis Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Osteoporosis Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Osteoporosis Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Osteoporosis Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Osteoporosis Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Osteoporosis Biosimilars.
This report presents a comprehensive overview, market shares, and growth opportunities of Osteoporosis Biosimilars market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
250渭驳/尘尝
60 mg/mL
70 mg/mL
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Biosidus SA
Cadila Pharmaceuticals
Gedeon Richter Australia Pty Ltd
Mochida Pharmaceutical Co., Ltd
STADA Arzneimittel AG
Alvogen, Inc
Theramex Ireland Ltd
Intas Pharmaceuticals Ltd
Sun Pharma ANZ Pty Ltd
Strides Pharma
Apotex Corp
Teva Pharmaceuticals, Inc
Novartis AG
Cipla Ltd
CrownBio Science (Jilin) Co., Ltd
LianKang Biotechnology Group
Shanghai United Cell Bioengineering Co., Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd
Shandong Boyan Biotechnology Co., Ltd
Mabwell (Shanghai) Biotechnology
Qilu Pharmaceutical Co., Ltd
Key Questions Addressed in this Report
What is the 10-year outlook for the global Osteoporosis Biosimilars market?
What factors are driving Osteoporosis Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Osteoporosis Biosimilars market opportunities vary by end market size?
How does Osteoporosis Biosimilars break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Osteoporosis Biosimilars Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Osteoporosis Biosimilars by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Osteoporosis Biosimilars by Country/Region, 2020, 2024 & 2031
2.2 Osteoporosis Biosimilars Segment by Type
2.2.1 250渭驳/尘尝
2.2.2 60 mg/mL
2.2.3 70 mg/mL
2.3 Osteoporosis Biosimilars Sales by Type
2.3.1 Global Osteoporosis Biosimilars Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Osteoporosis Biosimilars Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Osteoporosis Biosimilars Sale Price by Type (2020-2025)
2.4 Osteoporosis Biosimilars Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Osteoporosis Biosimilars Sales by Application
2.5.1 Global Osteoporosis Biosimilars Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Osteoporosis Biosimilars Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Osteoporosis Biosimilars Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Osteoporosis Biosimilars Breakdown Data by Company
3.1.1 Global Osteoporosis Biosimilars Annual Sales by Company (2020-2025)
3.1.2 Global Osteoporosis Biosimilars Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Osteoporosis Biosimilars Annual Revenue by Company (2020-2025)
3.2.1 Global Osteoporosis Biosimilars Revenue by Company (2020-2025)
3.2.2 Global Osteoporosis Biosimilars Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Osteoporosis Biosimilars Sale Price by Company
3.4 Key Manufacturers Osteoporosis Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Osteoporosis Biosimilars Product Location Distribution
3.4.2 Players Osteoporosis Biosimilars Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Osteoporosis Biosimilars by Geographic Region
4.1 World Historic Osteoporosis Biosimilars 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Osteoporosis Biosimilars Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Osteoporosis Biosimilars Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Osteoporosis Biosimilars 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Osteoporosis Biosimilars Annual Sales by Country/Region (2020-2025)
4.2.2 Global Osteoporosis Biosimilars Annual Revenue by Country/Region (2020-2025)
4.3 Americas Osteoporosis Biosimilars Sales Growth
4.4 APAC Osteoporosis Biosimilars Sales Growth
4.5 Europe Osteoporosis Biosimilars Sales Growth
4.6 Middle East & Africa Osteoporosis Biosimilars Sales Growth
5 Americas
5.1 Americas Osteoporosis Biosimilars Sales by Country
5.1.1 Americas Osteoporosis Biosimilars Sales by Country (2020-2025)
5.1.2 Americas Osteoporosis Biosimilars Revenue by Country (2020-2025)
5.2 Americas Osteoporosis Biosimilars Sales by Type (2020-2025)
5.3 Americas Osteoporosis Biosimilars Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Osteoporosis Biosimilars Sales by Region
6.1.1 APAC Osteoporosis Biosimilars Sales by Region (2020-2025)
6.1.2 APAC Osteoporosis Biosimilars Revenue by Region (2020-2025)
6.2 APAC Osteoporosis Biosimilars Sales by Type (2020-2025)
6.3 APAC Osteoporosis Biosimilars Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Osteoporosis Biosimilars by Country
7.1.1 Europe Osteoporosis Biosimilars Sales by Country (2020-2025)
7.1.2 Europe Osteoporosis Biosimilars Revenue by Country (2020-2025)
7.2 Europe Osteoporosis Biosimilars Sales by Type (2020-2025)
7.3 Europe Osteoporosis Biosimilars Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Osteoporosis Biosimilars by Country
8.1.1 Middle East & Africa Osteoporosis Biosimilars Sales by Country (2020-2025)
8.1.2 Middle East & Africa Osteoporosis Biosimilars Revenue by Country (2020-2025)
8.2 Middle East & Africa Osteoporosis Biosimilars Sales by Type (2020-2025)
8.3 Middle East & Africa Osteoporosis Biosimilars Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Osteoporosis Biosimilars
10.3 Manufacturing Process Analysis of Osteoporosis Biosimilars
10.4 Industry Chain Structure of Osteoporosis Biosimilars
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Osteoporosis Biosimilars Distributors
11.3 Osteoporosis Biosimilars Customer
12 World Forecast Review for Osteoporosis Biosimilars by Geographic Region
12.1 Global Osteoporosis Biosimilars 麻豆原创 Size Forecast by Region
12.1.1 Global Osteoporosis Biosimilars Forecast by Region (2026-2031)
12.1.2 Global Osteoporosis Biosimilars Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Osteoporosis Biosimilars Forecast by Type (2026-2031)
12.7 Global Osteoporosis Biosimilars Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Biosidus SA
13.1.1 Biosidus SA Company Information
13.1.2 Biosidus SA Osteoporosis Biosimilars Product Portfolios and Specifications
13.1.3 Biosidus SA Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Biosidus SA Main Business Overview
13.1.5 Biosidus SA Latest Developments
13.2 Cadila Pharmaceuticals
13.2.1 Cadila Pharmaceuticals Company Information
13.2.2 Cadila Pharmaceuticals Osteoporosis Biosimilars Product Portfolios and Specifications
13.2.3 Cadila Pharmaceuticals Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Cadila Pharmaceuticals Main Business Overview
13.2.5 Cadila Pharmaceuticals Latest Developments
13.3 Gedeon Richter Australia Pty Ltd
13.3.1 Gedeon Richter Australia Pty Ltd Company Information
13.3.2 Gedeon Richter Australia Pty Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.3.3 Gedeon Richter Australia Pty Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Gedeon Richter Australia Pty Ltd Main Business Overview
13.3.5 Gedeon Richter Australia Pty Ltd Latest Developments
13.4 Mochida Pharmaceutical Co., Ltd
13.4.1 Mochida Pharmaceutical Co., Ltd Company Information
13.4.2 Mochida Pharmaceutical Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.4.3 Mochida Pharmaceutical Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Mochida Pharmaceutical Co., Ltd Main Business Overview
13.4.5 Mochida Pharmaceutical Co., Ltd Latest Developments
13.5 STADA Arzneimittel AG
13.5.1 STADA Arzneimittel AG Company Information
13.5.2 STADA Arzneimittel AG Osteoporosis Biosimilars Product Portfolios and Specifications
13.5.3 STADA Arzneimittel AG Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 STADA Arzneimittel AG Main Business Overview
13.5.5 STADA Arzneimittel AG Latest Developments
13.6 Alvogen, Inc
13.6.1 Alvogen, Inc Company Information
13.6.2 Alvogen, Inc Osteoporosis Biosimilars Product Portfolios and Specifications
13.6.3 Alvogen, Inc Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Alvogen, Inc Main Business Overview
13.6.5 Alvogen, Inc Latest Developments
13.7 Theramex Ireland Ltd
13.7.1 Theramex Ireland Ltd Company Information
13.7.2 Theramex Ireland Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.7.3 Theramex Ireland Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Theramex Ireland Ltd Main Business Overview
13.7.5 Theramex Ireland Ltd Latest Developments
13.8 Intas Pharmaceuticals Ltd
13.8.1 Intas Pharmaceuticals Ltd Company Information
13.8.2 Intas Pharmaceuticals Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.8.3 Intas Pharmaceuticals Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Intas Pharmaceuticals Ltd Main Business Overview
13.8.5 Intas Pharmaceuticals Ltd Latest Developments
13.9 Sun Pharma ANZ Pty Ltd
13.9.1 Sun Pharma ANZ Pty Ltd Company Information
13.9.2 Sun Pharma ANZ Pty Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.9.3 Sun Pharma ANZ Pty Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Sun Pharma ANZ Pty Ltd Main Business Overview
13.9.5 Sun Pharma ANZ Pty Ltd Latest Developments
13.10 Strides Pharma
13.10.1 Strides Pharma Company Information
13.10.2 Strides Pharma Osteoporosis Biosimilars Product Portfolios and Specifications
13.10.3 Strides Pharma Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Strides Pharma Main Business Overview
13.10.5 Strides Pharma Latest Developments
13.11 Apotex Corp
13.11.1 Apotex Corp Company Information
13.11.2 Apotex Corp Osteoporosis Biosimilars Product Portfolios and Specifications
13.11.3 Apotex Corp Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Apotex Corp Main Business Overview
13.11.5 Apotex Corp Latest Developments
13.12 Teva Pharmaceuticals, Inc
13.12.1 Teva Pharmaceuticals, Inc Company Information
13.12.2 Teva Pharmaceuticals, Inc Osteoporosis Biosimilars Product Portfolios and Specifications
13.12.3 Teva Pharmaceuticals, Inc Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Teva Pharmaceuticals, Inc Main Business Overview
13.12.5 Teva Pharmaceuticals, Inc Latest Developments
13.13 Novartis AG
13.13.1 Novartis AG Company Information
13.13.2 Novartis AG Osteoporosis Biosimilars Product Portfolios and Specifications
13.13.3 Novartis AG Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Novartis AG Main Business Overview
13.13.5 Novartis AG Latest Developments
13.14 Cipla Ltd
13.14.1 Cipla Ltd Company Information
13.14.2 Cipla Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.14.3 Cipla Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Cipla Ltd Main Business Overview
13.14.5 Cipla Ltd Latest Developments
13.15 CrownBio Science (Jilin) Co., Ltd
13.15.1 CrownBio Science (Jilin) Co., Ltd Company Information
13.15.2 CrownBio Science (Jilin) Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.15.3 CrownBio Science (Jilin) Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 CrownBio Science (Jilin) Co., Ltd Main Business Overview
13.15.5 CrownBio Science (Jilin) Co., Ltd Latest Developments
13.16 LianKang Biotechnology Group
13.16.1 LianKang Biotechnology Group Company Information
13.16.2 LianKang Biotechnology Group Osteoporosis Biosimilars Product Portfolios and Specifications
13.16.3 LianKang Biotechnology Group Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 LianKang Biotechnology Group Main Business Overview
13.16.5 LianKang Biotechnology Group Latest Developments
13.17 Shanghai United Cell Bioengineering Co., Ltd
13.17.1 Shanghai United Cell Bioengineering Co., Ltd Company Information
13.17.2 Shanghai United Cell Bioengineering Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.17.3 Shanghai United Cell Bioengineering Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Shanghai United Cell Bioengineering Co., Ltd Main Business Overview
13.17.5 Shanghai United Cell Bioengineering Co., Ltd Latest Developments
13.18 Shenzhen Salubris Pharmaceuticals Co., Ltd
13.18.1 Shenzhen Salubris Pharmaceuticals Co., Ltd Company Information
13.18.2 Shenzhen Salubris Pharmaceuticals Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.18.3 Shenzhen Salubris Pharmaceuticals Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Shenzhen Salubris Pharmaceuticals Co., Ltd Main Business Overview
13.18.5 Shenzhen Salubris Pharmaceuticals Co., Ltd Latest Developments
13.19 Shandong Boyan Biotechnology Co., Ltd
13.19.1 Shandong Boyan Biotechnology Co., Ltd Company Information
13.19.2 Shandong Boyan Biotechnology Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.19.3 Shandong Boyan Biotechnology Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Shandong Boyan Biotechnology Co., Ltd Main Business Overview
13.19.5 Shandong Boyan Biotechnology Co., Ltd Latest Developments
13.20 Mabwell (Shanghai) Biotechnology
13.20.1 Mabwell (Shanghai) Biotechnology Company Information
13.20.2 Mabwell (Shanghai) Biotechnology Osteoporosis Biosimilars Product Portfolios and Specifications
13.20.3 Mabwell (Shanghai) Biotechnology Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Mabwell (Shanghai) Biotechnology Main Business Overview
13.20.5 Mabwell (Shanghai) Biotechnology Latest Developments
13.21 Qilu Pharmaceutical Co., Ltd
13.21.1 Qilu Pharmaceutical Co., Ltd Company Information
13.21.2 Qilu Pharmaceutical Co., Ltd Osteoporosis Biosimilars Product Portfolios and Specifications
13.21.3 Qilu Pharmaceutical Co., Ltd Osteoporosis Biosimilars Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Qilu Pharmaceutical Co., Ltd Main Business Overview
13.21.5 Qilu Pharmaceutical Co., Ltd Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
